Abstract:
Global trends in the pharmaceutical sector indicate that monoclonal antibodies (mAb) will be among the blockbuster drugs of the future. However, mAb therapies can be very expensive, which can be prohibitive to their use – almost irrespectively of their efficacy in treating disease. There is thus an immediate need to reduce the cost of mAb therapies. This presentation will discuss our recent "bioconjugate approaches" that contribute towards this goal and which e.g., improve the efficiency of key manufacturing steps and overcome viscosity challenges that prevent injection (less costly to administer than infusion). Moreover, this talk will expose some recent findings from our group that have the potential to facilitate the R&D process, especially for bispecific antibodies (bsAb) that are emerging variants of mAb that has shown promise in cancer treatment.